-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting Talaris Therapeutics (NASDAQ:TALS) & Pluri (NASDAQ:PLUR)
Contrasting Talaris Therapeutics (NASDAQ:TALS) & Pluri (NASDAQ:PLUR)
Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Pluri (NASDAQ:PLUR – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Profitability
This table compares Talaris Therapeutics and Pluri's net margins, return on equity and return on assets.
Get Talaris Therapeutics alerts:Net Margins | Return on Equity | Return on Assets | |
Talaris Therapeutics | N/A | -31.84% | -30.39% |
Pluri | N/A | -103.57% | -49.99% |
Volatility & Risk
Talaris Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
Insider & Institutional Ownership
65.4% of Talaris Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Pluri shares are owned by institutional investors. 16.6% of Talaris Therapeutics shares are owned by insiders. Comparatively, 5.4% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.Earnings & Valuation
This table compares Talaris Therapeutics and Pluri's top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Talaris Therapeutics | N/A | N/A | -$47.83 million | ($1.66) | -0.74 |
Pluri | $230,000.00 | 149.09 | -$41.24 million | N/A | N/A |
Pluri has higher revenue and earnings than Talaris Therapeutics.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Talaris Therapeutics and Pluri, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Talaris Therapeutics | 0 | 2 | 1 | 0 | 2.33 |
Pluri | 0 | 0 | 0 | 0 | N/A |
Talaris Therapeutics currently has a consensus target price of $14.80, indicating a potential upside of 1,103.25%. Given Talaris Therapeutics' higher possible upside, research analysts plainly believe Talaris Therapeutics is more favorable than Pluri.
Summary
Talaris Therapeutics beats Pluri on 7 of the 9 factors compared between the two stocks.
About Talaris Therapeutics
(Get Rating)
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
About Pluri
(Get Rating)
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation; and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the U.S. Department of Defense. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Pluri (NASDAQ:PLUR – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.
塔拉里斯治療公司(納斯達克:TALS-GET評級)和普魯裏(納斯達克:PLUR-GET評級)都是小盤醫療公司,但哪隻股票更好?我們將根據這兩家公司的機構所有權、分析師建議、估值、盈利能力、收益、股息和風險的實力進行比較。
Profitability
盈利能力
This table compares Talaris Therapeutics and Pluri's net margins, return on equity and return on assets.
下表比較了Talaris Treeutics和Pluri的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Talaris Therapeutics | N/A | -31.84% | -30.39% |
Pluri | N/A | -103.57% | -49.99% |
淨利潤率 | 股本回報率 | 資產回報率 | |
塔拉里斯治療公司 | 不適用 | -31.84% | -30.39% |
普魯裏 | 不適用 | -103.57% | -49.99% |
Volatility & Risk
波動性與風險
Talaris Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
Talaris Treateutics的貝塔係數為1.98,表明其股價的波動性比標準普爾500指數高98%。相比之下,Pluri的貝塔係數為1.56,這表明其股價的波動性比標準普爾500指數高56%。
Insider & Institutional Ownership
內部人與機構所有權
Earnings & Valuation
收益與估值
This table compares Talaris Therapeutics and Pluri's top-line revenue, earnings per share and valuation.
此表比較了Talaris Treeutics和Pluri的營收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Talaris Therapeutics | N/A | N/A | -$47.83 million | ($1.66) | -0.74 |
Pluri | $230,000.00 | 149.09 | -$41.24 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
塔拉里斯治療公司 | 不適用 | 不適用 | -4,783萬元 | ($1.66) | -0.74 |
普魯裏 | $230,000.00 | 149.09 | -4,124萬元 | 不適用 | 不適用 |
Pluri has higher revenue and earnings than Talaris Therapeutics.
Pluri的收入和收益比Talaris治療公司高。
Analyst Ratings
分析師評級
This is a breakdown of recent recommendations and price targets for Talaris Therapeutics and Pluri, as reported by MarketBeat.
據MarketBeat報道,這是Talaris治療公司和Pluri公司最近的建議和價格目標的細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Talaris Therapeutics | 0 | 2 | 1 | 0 | 2.33 |
Pluri | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
塔拉里斯治療公司 | 0 | 2 | 1 | 0 | 2.33 |
普魯裏 | 0 | 0 | 0 | 0 | 不適用 |
Talaris Therapeutics currently has a consensus target price of $14.80, indicating a potential upside of 1,103.25%. Given Talaris Therapeutics' higher possible upside, research analysts plainly believe Talaris Therapeutics is more favorable than Pluri.
Talaris治療公司目前的共識目標價為14.80美元,表明潛在上行空間為1103.25%。考慮到Talaris治療公司更高的可能上行空間,研究分析師顯然認為Talaris治療公司比Pluri更有利。
Summary
摘要
Talaris Therapeutics beats Pluri on 7 of the 9 factors compared between the two stocks.
Talaris治療公司在兩隻股票之間比較的9個因素中有7個擊敗了Pluri。
About Talaris Therapeutics
關於Talaris Treateutics
(Get Rating)
(獲取評級)
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Talaris治療公司在美國是一家臨牀晚期細胞治療公司。該公司致力於開發異基因造血幹細胞移植的方法,以改變實體器官移植和嚴重的自身免疫性疾病以及嚴重的非惡性血液、免疫和代謝疾病的護理標準。它的主要候選產品是FCR001,這是一種新型同種異體細胞療法,正處於活體腎移植患者的第二階段試驗。該公司還在開發用於已故捐贈者腎臟移植的FCR002;用於嚴重硬皮病患者的FCR001;以及用於一種或多種嚴重的非惡性血液、免疫或代謝疾病的FCR001。Talaris治療公司成立於1988年,總部設在肯塔基州的路易斯維爾。
About Pluri
關於Pluri
(Get Rating)
(獲取評級)
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation; and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the U.S. Department of Defense. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Pluri Inc.是一家生物技術公司,專注於開發基於胎盤的細胞治療產品,用於治療炎症、肌肉損傷和血液疾病。該公司開發以胎盤擴大(PLX)為基礎的細胞治療產品,包括針對髖部骨折手術後肌肉恢復的PLX-PAD處於第三階段臨牀試驗;與特拉維夫Sourasky醫學中心合作治療激素難治性移植物抗宿主疾病的I/II階段臨牀試驗;以及治療與新冠肺炎相關的急性呼吸窘迫綜合徵的第二階段臨牀試驗和骨髓移植後不完全恢復的第一階段臨牀試驗。該公司還開發了用於造血細胞移植後不完全造血恢復的PLX-R18,以及通過在美國與美國國立衞生研究院和美國國防部合作治療急性輻射綜合徵的解決方案。該公司前身為PluriStem治療公司,並於2022年7月更名為Pluri公司。Pluri Inc.成立於2001年,總部設在以色列海法。
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Talaris治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Talaris治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧